Research
Hormonal
Younger individuals (≤50 years) experience more significant weight and waist circumference reductions from Survodutide compared to older individuals (>50 years).
If you are 50 years or younger, you may experience greater weight loss from Survodutide than those over 50. This is likely due to metabolic differences and fewer comorbidities in younger patients, but the drug remains effective across age groups.
ModerateQualifiesMEDIUM confidence
In addition, changes in weight and WC in people ≤ 50 years of age under Survodutide intervention were more than in people > 50 years of age.
Why this rating
Based on subgroup analysis; while statistically significant, it is an observational finding within the meta-analysis.
Source
Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
Haijun Wan et al. · Diabetology & Metabolic Syndrome · 2024
DOI 10.1186/s13098-024-01501-x
Meta-analysis · 5 studiesCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Survodutide, a dual glucagon and GLP-1 receptor agonist, produces significant weight loss, BMI reduction, and waist circumference reduction in adults with overweight or obesity.Good
- The efficacy of Survodutide for weight loss is conditional on dose and duration, with doses >2 mg/week and interventions >16 weeks yielding significantly greater reductions in weight and waist circumference.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →